Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

by Ysios Capital

1 year ago
Non-Muscle-Invasive Bladder Cancer (NMIBC), bel-sar, Aura Biosciences

Aura Biosciences today announced positive data from a completed Phase 1 window of opportunity trial of bel-sar (AU-011) in patients with NMIBC. These data were presented by Dr. Seth Lerner as a late b...

Aura Biosciences has reported Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early - Stage Choroidal Melanoma

by Ysios Capital

2 years ago
bel-sar (AU-011), NMIBC, Aura Biosciences

Bel-sar is a virus-like drug conjugate, designed to have a dual mechanism of action, that induces direct tumor cell necrosis and elicits a robust and durable anti-tumor immune response.

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

by Ysios Capital

2 years ago
Aura Biosciences, choroidal melanoma (CM), bel-sar (AU-011)

Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

by Ysios Capital

4 years ago
Belzupacap Sarotalocan (AU-011), Aura Biosciences

Aura Biosciences today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’s first VDC product candidate, for the treatment of Non-Muscle Inv...

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

by Ysios Capital

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care.

Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ

by Ysios Capital

5 years ago
Ysios Capital, Aura Biosciences

Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on th...

Aura Biosciences, supported by Ysios Capital, Announces Oversubscribed $80 Million Financing

by Ysios Capital

5 years ago
Aura Biosciences, Ysios Capital, Life Sciences

Aura Biosciences, a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the closing of an oversubsc...

Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

7 years ago
Ysios Capital, Aura Biosciences, Lundbeckfonden, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with